Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial

Time-limited intensive glycaemic management using a combination of agents that achieves HbA1c levels below 6.5% in established diabetes is associated with glycaemic control more than 1 year after therapy is relaxed